Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Infarct

imatinib mesylate has been researched along with Infarct in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E1
Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C1
Bernardini, K; Buratti, T; Lanthaler, AJ; Mitterer, M1

Other Studies

3 other study(ies) available for imatinib mesylate and Infarct

ArticleYear
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
    Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

    Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2015
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
    Leukemia research, 2002, Volume: 26, Issue:9

    Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy

2002
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
    American journal of hematology, 2006, Volume: 81, Issue:3

    Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Erythromelalgia; Etoposide; Female; Humans; Hydroxyurea; Imatinib Mesylate; Infarction; Interferon-alpha; Kidney; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiography

2006